Cixutumumab

Expert Opinion on Investigational Drugs

Volumn 18, Issue 7, 2009, Pages 1025-1033

  McKian, Kevin P ^a   Haluska, Paul ^a  

^a Mayo Clinic   (United States)

Author keywords

Cixutumumab; IGF 1R; IMC A12; Monoclonal antibody

Indexed keywords

ANTIESTROGEN; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC A 12; IRINOTECAN; LAPATINIB; MELPHALAN; MITOTANE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PREDNISONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACNE; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOID; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; ERUCTATION; EWING SARCOMA; FATIGUE; GENE EXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; INFECTION; INJECTION SITE REACTION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDIASTINUM TUMOR; METASTASIS; NAUSEA; NEPHROTOXICITY; OVARY ADENOCARCINOMA; PANCREAS CANCER; PANCREAS ISLET CELL CARCINOMA; PARESTHESIA; PHEOCHROMOCYTOMA; PROSTATE CANCER; PRURITUS; PSORIASIS; RECURRENT CANCER; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; THYMOMA; THYROID CANCER; WEIGHT GAIN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 67650436410     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903055049     Document Type: Review

References (47)

1. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18 Pt 2):5549s-5555s
2. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277(42):39684-95
3. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18
4. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1-6
5. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-93
6. Blakesely VA, Butler AA, Koval AP, et al. IGF-I receptor function. In: Rosenfeld RG, Robers CT Jr, editors, The IGF system: molecular biology, physiology, and clinical applications. New Jersey: Humana Press; 1999. p. 143-63
7. Remacle-Bonnet M, Garrouste F, Baillat G, et al. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am J Pathol 2005;167(3):761-73
8. Zhang X, Lin M, van Golen KL, et al. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 2005;93(2):159-68
9. Siri S, Chen MJ, Chen TT. Biological activity of rainbow trouth Ea4-peptide of the pro-insulin-like growth factor (pro-IGF)-I on promoting attachment of breast cancer cells (MDA-MB-231) via alpha2- and beta1-integrin. J Cell Biochem 2006;99(6):1524-35
10. Pandini G, Vigneri R, Constantino A, et al. Insulin and insulin-like-growth factor-I (IGF-I) receptor overexpression in breast cancers lead to insulin/IGF-1 hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;57:1935-44
11. Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001;863:972-9
12. Guerra FK, Eijan AM, Puricelli L, et al. Varying patterns of expression of insulin-like growth factors I an II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer 1996;65:812-20
13. Burtrum D, Zhu Z, Lu D, et al. A Fully human monoclonal antibody to the insulin-like-growth factor I receptor blocks ligand-dependent signaling and inhibits tumor growth in vivo. Cancer Res 2003;63:8912-21
14. Wang Z, Chakravarty G, Kim S, et al. Growth-inhibitory effects of human anti-insulin-like growth factor I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 2006;12:4755-65
15. Wu KD, Zhou L, Burtrum D, et al. Antibody targeting of the insulin-like-growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007;56:343-57
16. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-83
17. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74
18. Anti-insulin-like growth factor-I receptor (IGF-1R) monoclonal antibody investigator's brochure. Imclone Systems, Inc.; 2006
19. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R mediated growth in hematopoietic cells. Leukemia 2006;20:1254-60
20. Tonra JR, Deevi DS, Corcoran E, et al. Combined antibody mediated inhibition of IGF-1R, EGFR, VEGFR2 for more consistent and greater anti-tumor effects. Eur J Cancer 2006;4:207
21. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 2006;66:1500-8
22. Available from: www.clincaltrials.gov
23. Wu JD, Haugk K, Coleman I, et al. Combine in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 2006;12(20 Pt 1):6153-60
24. Dunn SE, Hardman RA, Kari FW, Barret JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57(13):2687-93
25. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF-1) rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999;56(1):1-10
26. Lee JY, Han CY, Yang JW, et al. al. Induction of glutathione transferase in insulin-like growth factor type I receptor-overexpressed hepatoma cells. Mol Pharmacol 2007;72(4):1082-93
27. Devita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975;35(1):98-110
28. Vasilcanu R, Vasilcanu D, Rosengren L, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin 1. Oncogene 2008;2711:1629-38
29. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11:22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990;86(6):1806-14
30. Scotlandi K, Manara MC, Nicoletti G, et al. al. Antitumor activity of the insulin-like growth factor I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65(9):3868-76
31. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007;67(3):1155-62
32. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001;276(13):9817-24
33. Parisot JP, Hu XF, DeLuise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 1999;79(5-6):693-700
34. Knowlden JM, Hutcheson IR, Barrow D, et al. Insulin-like growth factor I receptor signaling in tamoxifen resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18
35. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008;68(3):826-33
36. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93(24):1852-7
37. Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor 1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65(23):11118-28
38. Haluska P, Carboni JM, Ten Eyck C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7(9):2589-98
39. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005;7:R570-9
40. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor 1 mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phospoinositide 3-kinase signaling. Cancer Res 2002;62:200-7
41. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R dependent mechanism. Oncogene 2006
42. Higano CS, Yu EY, Whiting SH, et al. A phase I, first in man study of weekly IMC-A12, a fully human insulin-like growth factor receptor IgG1 monoclonal antibody in patients with advanced solid tumors. ASCO 2007:A269
43. Rothenberg ML, Poplin E, Sandler AB, et al. Phase I dose-escalation study of the anti-IGF-IR recominant IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. Mol Targets Cancer Ther 2007
44. Karp DD, Paz-Ares LG, Novello S, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 2009 [Epub ahead of print]
45. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Can Res 2007;13(19):5834-40
46. Frogen T, Jepsen JS, Larsen SS, et al. Antiestrogen resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005;12:599-614
47. Ye JJ, Liang SJ, Guo N, et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003;35:836-42